Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

Stock Information for Verrica Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Verrica Pharmaceuticals Inc.

Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.